ALMKT:EPA
Mauna Kea Technologies SA
0,098 €
arrow_upward
+1,34%(+0,0013) 1D
29 ოქტ, 12:25:40 GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALMKT...
Open
0,10 €
High
0,10 €
Low
0,10 €
Mkt. cap
18,87 მლნ.
Avg. vol.
470,68 ათ.
Volume
180,41 ათ.
P/E ratio
0,83
52-wk high
0,23 €
52-wk low
0,07 €
EPS
0,12 €
Shares outstanding
195,26 მლნ.
No. of employees
56
Open
0,10 €
High
0,10 €
Low
0,10 €
Mkt. cap
18,87 მლნ.
Avg. vol.
470,68 ათ.
Volume
180,41 ათ.
P/E ratio
0,83
52-wk high
0,23 €
52-wk low
0,07 €
EPS
0,12 €
Shares outstanding
195,26 მლნ.
No. of employees
56
News stories
From web sources and news partners
FinancialContent
·
23 წუთის წინ
Granite Construction (NYSE:GVA) delivers impressive Q3 2026, full-year outlook slightly exceeds expectations
lincolnjournal.com
·
1 საათის წინ
Stagwell Inc. (NASDAQ:STGW) Reports Results for the Three and Nine Months Ended September 30, 2026
24/7 Wall St.
·
42 წუთის წინ
4 Dividend-Paying Dow Jones Industrial Stocks That Beat Q3 Estimates
Profile
Mauna Kea Technologies is a global medical device company focused on endomicroscopy, the field of microscopic imaging during endoscopy procedures. The company researches, develops and markets tools to visualize, detect, and rule out abnormalities including malignant and pre-malignant tumors or lesions in the gastrointestinal and pulmonary tracts.
The company makes Cellvizio, a probe-based Confocal Laser Endomicroscopy system, which provides physicians and researchers with real-time access to histological information during standard endoscopy procedures through high-resolution cellular imaging of internal tissues.
Cellvizio is used in medical applications such as gastrointestinal endoscopy, pulmonology and urology to help physicians diagnose lesions and make accurate treatment decisions in real-time.
Cellvizio went public in July 2011 and trades on the Euronext Paris exchange. Wikipedia
About Mauna Kea Technologies SA